# DESCRIPTION

## TECHNICAL FIELD

- define technical field of cancer diagnosis

## BACKGROUND

- describe limitations of current cancer diagnosis methods

## SUMMARY

- diagnose HCC using laminin gamma 2 monomer
- determine risk of HCC using laminin gamma 2 monomer
- monitor HCC progression using laminin gamma 2 monomer
- diagnose HCC using laminin gamma 2 monomer and PIVKA-II
- determine risk of HCC using laminin gamma 2 monomer and PIVKA-II
- monitor HCC progression using laminin gamma 2 monomer and PIVKA-II
- diagnose HCC using laminin gamma 2 monomer and AFP
- determine risk of HCC using laminin gamma 2 monomer and AFP
- monitor HCC progression using laminin gamma 2 monomer and AFP
- diagnose pancreatic cancer using laminin gamma 2 monomer and additional biomarkers
- determine risk of pancreatic cancer using laminin gamma 2 monomer and additional biomarkers
- monitor pancreatic cancer progression using laminin gamma 2 monomer and additional biomarkers

## DETAILED DESCRIPTION

- introduce biomarkers for cancer detection
- methods for diagnosing cancer using biomarkers

### 1. DEFINITIONS

- define technical terms
- introduce open-ended transitional phrases
- define numeric ranges
- define area under curve (AUC)
- define cancer
- define component
- define control subject
- define control group
- define label and detectable label
- describe detectable labels
- introduce acridinium compounds
- describe acridinium-9-carboxamide
- describe acridinium-9-carboxylate aryl ester
- define TNM system for staging hepatocellular carcinoma
- define stage I-IV hepatocellular carcinoma
- define liver cancer
- define liver cirrhosis and liver disease
- define liver fibrosis
- define neoplasia
- define normal control
- define benign pancreatic disease
- define early stage pancreatic cancer
- define late stage pancreatic cancer
- define stage 0 pancreatic cancer
- define stage I pancreatic cancer
- define stage II pancreatic cancer
- define stage III pancreatic cancer
- define stage IV pancreatic cancer
- define predetermined cutoff
- define pretreatment reagent
- define quality control reagents
- define risk assessment
- define sample
- define variant

### 2. METHOD OF DIAGNOSING A DISEASE USING LAMININ GAMMA 2 MONOMER

- introduce method of diagnosing disease
- describe obtaining sample from subject
- determine level of laminin gamma 2 monomer in sample
- compare level to reference level
- indicate disease presence or risk with level change
- describe optional additional biomarkers
- define laminin gamma 2 monomer
- describe structure and function of laminin gamma 2 monomer
- list additional biomarkers (PIVKA-II, AFP, CEA, CA19-9)
- describe PIVKA-II
- describe AFP
- describe CEA
- describe CA19-9
- describe combinations of biomarkers
- describe disease diagnosis (HCC or pancreatic cancer)
- define pancreatic cancer
- describe types of pancreatic cancer
- motivate diagnosing pancreatic cancer
- describe method of diagnosing pancreatic cancer
- describe measuring laminin gamma 2 monomer level
- describe measuring additional biomarkers
- describe diagnosing pancreatic cancer at different stages
- describe immunoassay to determine biomarker levels
- describe antibodies used in immunoassay
- describe sandwich ELISA
- describe application of sandwich ELISA
- describe method of diagnosing disease using laminin gamma 2 monomer
- outline sandwich assay format
- detail capture antibody-laminin gamma 2 monomer complex formation
- describe detection antibody-laminin gamma 2 monomer complex formation
- discuss reference levels for laminin gamma 2 monomer and additional biomarkers
- define predetermined levels for laminin gamma 2 monomer and additional biomarkers
- explain altered levels of laminin gamma 2 monomer and additional biomarkers
- provide typical or normal levels for laminin gamma 2 monomer and additional biomarkers
- list reference levels for laminin gamma 2 monomer in serum
- list reference levels for PIVKA-II in serum
- list reference levels for AFP in serum
- list reference levels for CEA in serum
- list reference levels for CA19-9 in serum
- describe methods for determining cutoff values

### 3. METHOD OF DETERMINING RISK OF DEVELOPING THE DISEASE

- determine risk of developing disease using biological sample and laminin gamma 2 monomer level

### 4. METHOD OF MONITORING PROGRESSION OF THE DISEASE

- obtain and compare biological samples to determine disease progression
- measure and compare laminin gamma 2 monomer levels in samples
- determine disease progression based on comparison of levels

### 5. KIT

- provide kit for performing methods
- include instructions for detecting biomarkers
- provide reagents for detecting biomarkers
- include reference standard for biomarkers
- provide antibodies for detecting biomarkers
- include containers for reagents
- provide calibrators and controls
- include buffers and solutions for assay
- provide instrument for obtaining test sample
- include solid phase for assay
- provide detectable label for assay
- include components for detecting label
- adapt kit for use in automated systems

### 6. EXAMPLES

- introduce example 1
- describe methods and materials for example 1
- analyze tumor markers for HCC in example 1
- perform statistical analysis in example 1
- introduce example 2
- establish laminin gamma 2 monomer immunoassay in example 2
- introduce example 3
- detect laminin gamma 2 monomer in specimens in example 3
- analyze serum concentration of laminin gamma 2 monomer in HCC stages in example 4
- present results
- show serum concentration of laminin gamma 2 monomer
- compare serum concentrations between HCC and healthy donor specimens
- examine specificity and sensitivity of laminin gamma 2 monomer as a marker for HCC
- generate ROC graph and calculate AUC
- determine optimal cutoff value
- compare sensitivity and specificity of laminin gamma 2 monomer with AFP and PIVKA-II
- examine positive rate of detecting HCC for laminin gamma 2 monomer and combinations thereof
- show positive rate of detecting HCC for different cutoff values
- present results for serum concentration of laminin gamma 2 monomer in stages III and IV of pancreatic cancer
- examine specificity and sensitivity of laminin gamma 2 monomer as a marker for pancreatic cancer
- generate ROC graph and calculate AUC for pancreatic cancer
- determine optimal cutoff value for pancreatic cancer
- compare sensitivity and specificity of laminin gamma 2 monomer with CEA and CA19-9
- examine positive rate of detecting pancreatic cancer for laminin gamma 2 monomer and combinations thereof
- show positive rate of detecting pancreatic cancer for different cutoff values
- conclude that laminin gamma 2 monomer is a marker for diagnosis of HCC and pancreatic cancer

## 7. CLAUSES

- define method of diagnosing hepatocellular carcinoma
- add additional biomarker to method
- compare levels of biomarkers to reference levels
- specify biomarkers to be determined in biological sample
- specify conditions for identifying HCC
- specify type of biological sample
- specify detection method for laminin gamma 2 monomer
- specify detection method for PIVKA-II and AFP
- specify type of immunoassay
- specify reference level of PIVKA-II and AFP
- specify reference level of laminin gamma 2 monomer
- specify cutoff level of laminin gamma 2 monomer
- specify method of determining cutoff level
- specify reference level of laminin gamma 2 monomer in calibrator
- define method of determining if subject has or is at risk of developing HCC
- add additional biomarker to method
- compare levels of biomarkers to reference levels
- specify biomarkers to be determined in biological sample
- specify conditions for identifying HCC
- specify type of biological sample
- define method of monitoring progression of HCC

